Keywords: لنالیدومید; Follicular lymphoma; Treatment; Obinutuzumab; Idelalisib; Ibrutinib; Venetoclax; Lenalidomide;
مقالات ISI لنالیدومید (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: لنالیدومید; Multiple myeloma; Toxic death; Early mortality; Newly diagnosed; Transplant-Ineligible; New drugs; Bortezomib; Lenalidomide; Thalidomide;
Keywords: لنالیدومید; Mantle cell lymphoma; Ibrutinib; Novel therapies; Bruton's tyrosine kinase inhibitors; Bortezomib; Lenalidomide; Relapsed; Refractory; Ibrutinib combinations;
Keywords: لنالیدومید; Parkinsonism; Lenalidomide; Creutzfeldt-Jakob disease; Prion disease;
Keywords: لنالیدومید; Multiple myeloma; Vaccination; Immunization; Lenalidomide; Maintenance; Autologous transplant;
Keywords: لنالیدومید; AE; adverse event; ADR; adverse drug reaction; ANC; absolute neutrophil count; CI; confidence interval; CR; complete remission; CTCAE; common terminology criteria for adverse events; DEX; dexamethasone; ECOG; eastern cooperative oncology group; eCRF; elec
Keywords: لنالیدومید; ASCT; CR; Lenalidomide; MM; Treatment intensification;
Keywords: لنالیدومید; Chronic lymphocytic leukemia; Maintenance; Anti-CD20 antibodies; Kinase-inhibitors; Lenalidomide; Long-term treatment;
Keywords: لنالیدومید; Bortezomib; Daratumumab; Dexamethasone; Epigenetic aberrations; Immunomodulatory drugs; Lenalidomide; Microenvironment; P-glycoprotein; Proteasome inhibitors;
Keywords: لنالیدومید; Prostate cancer; Metastatic castration-resistant prostate cancer; Circulating tumor cells; Docetaxel; Lenalidomide;
Keywords: لنالیدومید; Kidney allograft rejection; lenalidomide; multiple myeloma; kidney transplant; acute renal allograft rejection; immunomodulatory chemotherapy agent; chemotherapy regimen; malignancy; immunosuppression withdrawal; case report;
Keywords: لنالیدومید; CCMC; Commercial Claims and Medicare; CCI; Charlson Comorbidity Index; del(5q); deletion 5q abnormality; DOT; duration of therapy; DM; dose modification; ESAs; erythropoiesis-stimulating agents; G-CSF; granulocyte colony-stimulating factor; ICD-9-CM; Inte
Keywords: لنالیدومید; 5q Syndrome; azacitidine; chronic myelomonocytic leukaemia; International Prognostic Scoring System-R; lenalidomide; myelodysplastic syndrome;
Keywords: لنالیدومید; Clofarabine; Lenalidomide; Immune profiling;
Keywords: لنالیدومید; MDS; myelodysplastic syndromes; AML; acute myeloid leukemia; AZA; azacitidine; DEC; decitabine; LEN; lenalidomide; HI; hematological improvement; SKY; spectral karyotyping; CNV; copy number variation; IWG; International Working Group; HMA; hypomethylating
Keywords: لنالیدومید; Lenalidomide; Serum albumin; Spectrofluorimetric investigation; Molecular docking;
Keywords: لنالیدومید; Lenalidomide; Melphalan; Autologous stem cell transplantation; Relapsed and refractory multiple myeloma;
Keywords: لنالیدومید; Lymphatic vessels; Photodynamic therapy; Lenalidomide; Anti-PD-L1 antibody; checkpoint inhibitor;
Keywords: لنالیدومید; Bortezomib; BTK; Clinical trial; Copanlisib; Ibritumomab tiuxetan; Ibrutinib; Idelalisib; Lenalidomide; Marginal zone lymphoma; Obinutuzumab; PI3K; Radioimmunotherapy; Rituximab; TGR-1202; Ublituximab; Venetoclax;
Keywords: لنالیدومید; Thalidomide; Lenalidomide; Myeloma; Comparative effectiveness; Peripheral neuropathy; Survival;
Keywords: لنالیدومید; Lenalidomide; Chronic lymphocytic leukemia; Nonmyeloablative; Allogeneic; Transplantation;
Keywords: لنالیدومید; Bortezomib; High-risk myeloma; Lenalidomide; Maintenance therapy; RVD maintenance
Keywords: لنالیدومید; Chronic lymphocytic leukemia; Lenalidomide; Clinical efficacy; Immune activation; Microenvironment; Response prediction
Keywords: لنالیدومید; Mantle cell; Stem cell transplantation; Maintenance; MRD; Novel therapies; Bortezomib; Ibrutinib; Lenalidomide;
Keywords: لنالیدومید; Liver cancer; Progenitor cells; Thalidomide; Analogues; Lenalidomide; Sorafenib; Apoptosis; Mitosis; LPCs; liver progenitor cells; HCC; hepatocellular carcinoma; FDA; Federal Drug Administration; SAR; structure activity relationship; BMOL; bipotential mou
Keywords: لنالیدومید; Lenalidomide; Immunomodulatory drugs; Multiple myeloma; Myelodisplastic syndromes; Amyloidosis; Adverse cutaneous reactions; Stevens-Johnson syndrome; Erythema multiforme; Toxic epidermal necrolysis;
Keywords: لنالیدومید; szpiczak plazmocytowy; niewydolność nerek; talidomid; lenalidomid; bortezomib; karfilzomibMultiple myeloma; Renal insufficiency; Thalidomide; Lenalidomide; Bortesomib; Carfilzomib
Keywords: لنالیدومید; Continous treatment; Cytogenetic; Lenalidomide; Real life evaluation; Refractory-relapsed multiple myeloma;
Keywords: لنالیدومید; 5q deletion; Lenalidomide; MDS clinical practice; Myelodysplastic syndromes
Keywords: لنالیدومید; MDS; combination; lenalidomide; azacitidine; decitabine; vorinostat; mocetinostat; valproic acid
Keywords: لنالیدومید; AH; amyloid heavy chain; AL; amyloid light chain; ASCT; autologous stem cell transplant; ATTR; amyloid transthyretin; B-Dex; bortezomib and dexamethasone; BMDex; bortezomib plus melphalan and dexamethasone; BNP; brain natriuretic peptide; Bor; bortezomib;
Keywords: لنالیدومید; Multiple myeloma; Extramedullary plasmacytoma; Laser; Subglottis; Lenalidomide;
Keywords: لنالیدومید; Multiple myeloma; Lenalidomide; Allogeneic transplantation
Keywords: لنالیدومید; Idelalisib; Fludarabine; Lenalidomide; LC-MS/MS; Bioanalytical; Pharmacokinetics
Keywords: لنالیدومید; Chronic Lymphocytic Leukemia; Relapse; Lenalidomide; Tumor flare; Maintenance;
Keywords: لنالیدومید; Bortezomib; Cardiac amyloidosis; Cyclophosphamide; Lenalidomide; Light chain amyloidosis;
Keywords: لنالیدومید; Myelodysplastic syndrome (MDS); Systematic review; Clinical trials; Immunomodulatory agents; Lenalidomide; Thalidomide;
Keywords: لنالیدومید; 5q minus; JAK2 V617F mutation; RARS-T; MDS; Lenalidomide
Keywords: لنالیدومید; Bortezomib; Carfilzomib; Cytogenetics; Dexamethasone; Immunotherapy; Lenalidomide; Next-generation sequencing
Keywords: لنالیدومید; Acute myeloid leukemia; Clinical trial; Cytarabine; Lenalidomide; Phase I; Relapse/refractory AML
Keywords: لنالیدومید; ARDS; Lenalidomide; Drug toxicity
Lenalidomide acesulfamate: Crystal structure, solid state characterization and dissolution performance
Keywords: لنالیدومید; Pharmaceutical salt; Solubilization; Intermolecular interactions; Lenalidomide; Artificial sweetener;
Lenalidomide induced durable remission in a patient with MDS/MPN-with ring sideroblasts and thrombocytosis with associated 5q- syndrome
Keywords: لنالیدومید; MDS/MPN; Ring sideroblast; Thrombocytosis; 5q; Lenalidomide;
Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients)
Keywords: لنالیدومید; Myelodysplastic syndromes; Lenalidomide; Del(5q) aberration; Erythropoietin; Prednisone;
SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q
Keywords: لنالیدومید; Del(5q); Hypomethylating agent; Lenalidomide; MDS; Treatment algorithm;
Lenalidomide regulates osteocytes fate and related osteoclastogenesis via IL-1β/NF-κB/RANKL signaling
Keywords: لنالیدومید; Lenalidomide; Osteocyte; NF-κB; RANKL; Osteoclastogenesis; Osteoarthritis;
POEMS Syndrome
Keywords: لنالیدومید; POEMS syndrome; Autologous stem cell transplantation; VEGF; Lenalidomide; Thalidomide; Bortezomib;
What is the optimal initial management of the older MCL patient?
Keywords: لنالیدومید; Mantle cell lymphoma; Elderly patients; Induction therapy; Maintenance therapy; R-CHOP; Bendamustine; Cytarabine; Lenalidomide; Bortezomib; Toxicity;
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017
Keywords: لنالیدومید; Autologous transplantation; Daratumumab; Lenalidomide; Minmal residual disease; Smoldering myeloma;
Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma
Keywords: لنالیدومید; Multiple myeloma; Panobinostat; Heme oxygenase-1; IRF4; Lenalidomide; Apoptosis;